Healthcare
Live Price
Offline$463.28
+2.24% today
1Y Change
-8.79%
Window
Jun 30, 2025 → Jun 23, 2026
Coverage: 246 bars · Jun 30, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Chemed Corp (CHE) is a Healthcare stock with a market cap of $5.68B and listed on NYSE. The stock last traded around $463.28 and down 8.8% across the available one-year price window (Jun 30, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of +4.1%, EPS growth of -8.4%, a dividend yield of 0.5%. What stands out right now is revenue +4.1%, EPS -8.4%, free cash flow -11.5% with operating margin 12.9% and ROIC 19.5%. The dividend is present but secondary, with a yield around 0.5%. Valuation is more restrained than many high-expectation growth names at P/E 22.5 and price/sales 2.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CHE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
CHE is 27.52 pts behind over the shared 1Y window.
CHE had 15.17 pts deeper max drawdown than SPY.
CHE beat SPY in 0 of 2 calendar years shown and trailed in 2.
CHE
-8.79%
Normalized return
SPY
+18.73%
S&P 500
Excess Return
-27.52 pts
Relative to SPY
CHE Max Drawdown
-24.30%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for CHE and SPY.
| Year | CHE | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +4.79% | +6.71% | -1.91 pts | SPY |
| 2025 | -11.52% | +11.19% | -22.72 pts | SPY |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.1B
+0.2% YoY
FY Net Income
$268.6M
+7.6% YoY
Free Cash Flow
$249.9M
-1.0% YoY
Revenue Growth
+4.1%
EPS Growth
-8.4%
Gross Margin
30.3%
Net Margin
10.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.5B | 2.4B | 2.3B | 2.1B | 2.1B |
| Gross Profit | 758M | 854M | 799M | 765M | 770M |
| Operating Income | 338M | 366M | 341M | 343M | 343M |
| EBITDA | 422M | 464M | 414M | 393M | 411M |
| Net Income | 265M | 302M | 273M | 250M | 269M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 75M | 178M | 264M | 74M | 33M |
| Total Assets | 1.6B | 1.7B | 1.7B | 1.4B | 1.3B |
| Total Liabilities | 661M | 550M | 560M | 643M | 719M |
| Shareholder Equity | 979M | 1.1B | 1.1B | 799M | 623M |
| Total Debt | 155M | 141M | 155M | 247M | 324M |
| Net Debt | 80M | -38M | -109M | 173M | 291M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
309M
-0.4% YoY
Capital Expenditures
59M
-2.4% YoY
Free Cash Flow
250M
-1.0% YoY
Key ratios
Gross Margin
30.3%
Operating Margin
12.9%
Net Margin
10.2%
ROE
25.3%
Debt / Equity
0.28x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.